What does the evidence say about Flaxseed Blood Lipids Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Flaxseed Blood Lipids Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Dyslipidemia is one of the most important modifiable risk factors for the development of CVD (). [Schwingshackl Lukas (2018); evidence level 1] - It is well-established that saturated fatty acids (SFAs), when replaced with either PUFAs or MUFAs, decrease LDL-cholesterol (LDL-C), a strong risk factor for CVD (). [Schwingshackl Lukas (2018); evidence level 1] - Moreover, consuming PUFAs instead of SFAs reduced coronary heart disease (CHD) events in randomized controlled trials (RCTs) (). [Schwingshackl Lukas (2018); evidence level 1] - 1 2 3 4 5 6 According to the most recent report from the Global Burden of Disease Study, CVD is the leading cause of death worldwide (). [Schwingshackl Lukas (2018); evidence level 1] - Histopathological analysis of the liver, kidney, and heart showed improved tissue structures, with T3 exhibiting the greatest overall improvement due to the balanced ratio of chickpea and flaxseed. [Zahid S (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.